Literature DB >> 30538744

Current Management of Polycystic Ovary Syndrome: From Bench to Bedside.

Antonio Simone Laganà1, Salvatore Giovanni Vitale2, Marco Noventa3, Amerigo Vitagliano3.   

Abstract

Entities:  

Year:  2018        PMID: 30538744      PMCID: PMC6261402          DOI: 10.1155/2018/7234543

Source DB:  PubMed          Journal:  Int J Endocrinol        ISSN: 1687-8337            Impact factor:   3.257


× No keyword cloud information.
Polycystic ovary syndrome (PCOS) affects 6–10% of women in reproductive age and is characterized by hyperandrogenism, insulin resistance, and chronic anovulation [1]. It is a heterogeneous syndrome with not completely understood etiology that is related to a complex interaction between metabolic, endocrine, genetic, and environmental factors. Increasing evidence suggests that insulin resistance and secondary hyperinsulinemia play a key synergistic role with hyperandrogenism in the development and maintenance of metabolic alterations and anovulation or irregular cycles in both obese and lean patients with PCOS [2]. On that basis, current treatment strategies aim at reducing insulin resistance in patients with PCOS and, consequently, to reach a reduction of compensatory hyperinsulinemia, improving metabolic and ovulatory features [3-5]. Insulin-sensitizer drugs are the recommended first-line therapy according to recent guidelines [6] for women with PCOS and metabolic abnormalities [7-9] with the aim at improving fertility [10-13], although physical activity and lifestyle change should be considered the first steps in overweight and obese PCOS patients to achieve weight loss [14, 15]. In this scenario, we are honored to introduce this special issue, which contains five articles that may shed new light on the topic. In particular, three articles are focused on metabolic disturbances in PCOS women: the first one (“Free Testosterone Reflects Metabolic as well as Ovarian Disturbances in Subfertile Oligomenorrheic Women”) found that sex hormone-binding globulin and calculated free testosterone are associated with both ovarian ultrasound and metabolic parameters, such as the body mass index (BMI) and insulin resistance, suggesting a pivotal role for androgen excess in PCOS-related subfertility and ovulatory dysfunction; the second article (“Pericardial Fat Relates to Disturbances of Glucose Metabolism in Women with the Polycystic Ovary Syndrome, but Not in Healthy Control Subjects”) found that pericardial fat measured using 1H-magnetic resonance spectroscopy and imaging is positively related to atherogenic lipid profiles, BMI, waist circumference, and liver fat in women with PCOS, suggesting it as a potential noninvasive tool to predict metabolic prognosis in this population; the third article (“Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome”) highlights that a low-dose combination of insulin sensitizers and an antiandrogen is able to normalize fetuin-A levels in adolescent girls with PCOS. Considering that high levels of fetuin-A have been associated with greater risks for type 2 diabetes and with features of metabolic syndrome, this treatment may significantly reduce metabolic consequences and prevent acute events. Besides these three articles related to metabolic disturbances and their treatment, another paper (“The Place of In Vitro Maturation in PCO/PCOS”) depicted a clear and accurate summary of available evidence regarding the optimization of culture media, laboratory protocols, pregnancy rates, and neonatal outcomes following in vitro maturation (IVM) of human oocytes in PCOS women, which are known to have a variable incidence of infertility and worse outcomes following assisted reproductive technology. Finally, the last paper (“Uterine Artery Doppler in Pregnancy: Women with PCOS Compared to Healthy Controls”) investigated differences in the uterine artery pulsatility index (UtAPI) between pregnant women with PCOS and healthy controls and explored the possible effects of metformin on this parameter. Interestingly, the authors found that there was no difference in the UtAPI between women with PCOS and healthy controls in the first and second trimesters of pregnancy; in addition, metformin was not found to have an immediate effect on the UtAPI. Overall, the manuscripts published in this special issue add significant and novel elements for the understanding of the etiology, pathophysiology, diagnosis, and treatment of this complex and multifaceted syndrome. We offer these new insights to the readers, hoping that they will stimulate further debate and address new fields of investigation in the next future.
  15 in total

1.  Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.

Authors:  Alfonsa Pizzo; Antonio Simone Laganà; Luisa Barbaro
Journal:  Gynecol Endocrinol       Date:  2013-12-19       Impact factor: 2.260

2.  Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS.

Authors:  Richard S Legro; William C Dodson; Allen R Kunselman; Christy M Stetter; Penny M Kris-Etherton; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; Kelly C Allison; David B Sarwer; Michael P Diamond; William D Schlaff; Peter R Casson; Gregory M Christman; Kurt T Barnhart; G Wright Bates; Rebecca Usadi; Scott Lucidi; Valerie Baker; Heping Zhang; Esther Eisenberg; Christos Coutifaris; Anuja Dokras
Journal:  J Clin Endocrinol Metab       Date:  2016-05-12       Impact factor: 5.958

3.  Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.

Authors:  Antonio Simone Laganà; Luisa Barbaro; Alfonsa Pizzo
Journal:  Arch Gynecol Obstet       Date:  2014-11-22       Impact factor: 2.344

Review 4.  Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.

Authors:  Antonio Simone Laganà; Simone Garzon; Jvan Casarin; Massimo Franchi; Fabio Ghezzi
Journal:  Trends Endocrinol Metab       Date:  2018-09-27       Impact factor: 12.015

5.  Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Antonio Simone Laganà; Amerigo Vitagliano; Marco Noventa; Guido Ambrosini; Rosario D'Anna
Journal:  Arch Gynecol Obstet       Date:  2018-08-04       Impact factor: 2.344

Review 6.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

7.  Effect of treatment with myo-inositol on semen parameters of patients undergoing an IVF cycle: in vivo study.

Authors:  Ferdinando Antonio Gulino; Emanuela Leonardi; Ilaria Marilli; Giulia Musmeci; Salvatore Giovanni Vitale; Vito Leanza; Marco Antonio Palumbo
Journal:  Gynecol Endocrinol       Date:  2015-09-11       Impact factor: 2.260

8.  Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS.

Authors:  Anuja Dokras; David B Sarwer; Kelly C Allison; Lauren Milman; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; Jennifer Fleming; Christos Coutifaris; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2016-06-02       Impact factor: 5.958

9.  Evidence-Based and Patient-Oriented Inositol Treatment in Polycystic Ovary Syndrome: Changing the Perspective of the Disease.

Authors:  Antonio Simone Laganà; Paola Rossetti; Fabrizio Sapia; Benito Chiofalo; Massimo Buscema; Gaetano Valenti; Agnese Maria Chiara Rapisarda; Salvatore Giovanni Vitale
Journal:  Int J Endocrinol Metab       Date:  2017-01-22

Review 10.  Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols.

Authors:  Antonio Simone Laganà; Paola Rossetti; Massimo Buscema; Sandro La Vignera; Rosita Angela Condorelli; Giuseppe Gullo; Roberta Granese; Onofrio Triolo
Journal:  Int J Endocrinol       Date:  2016-08-04       Impact factor: 3.257

View more
  2 in total

1.  Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe.

Authors:  Terhi T Piltonen; Maria Ruokojärvi; Helle Karro; Linda Kujanpää; Laure Morin-Papunen; Juha S Tapanainen; Elisabet Stener-Victorin; Inger Sundrström-Poromaa; Angelica L Hirschberg; Pernille Ravn; Dorte Glintborg; Jan Roar Mellembakken; Thora Steingrimsdottir; Melanie Gibson-Helm; Eszter Vanky; Marianne Andersen; Riikka K Arffman; Helena Teede; Kobra Falah-Hassani
Journal:  PLoS One       Date:  2019-12-26       Impact factor: 3.240

2.  Decrease in the Level of Nervonic Acid and Increased Gamma Linolenic Acid in the Plasma of Women with Polycystic Ovary Syndrome after a Three-month Low-glycaemic Index and Caloric Reduction Diet.

Authors:  Małgorzata Szczuko; Arleta Drozd; Dominika Maciejewska; Marta Zapałowska-Chwyć; Ewa Stachowska
Journal:  Open Life Sci       Date:  2019-07-10       Impact factor: 0.938

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.